| Identification | Back Directory | [Name]
Finerenone (BAY 94-8862) | [CAS]
1050477-31-0 | [Synonyms]
BAY948862
BAY 94-8862
Finerenone (BAY 94-8862)
(4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)- | [Molecular Formula]
C21H22N4O3 | [MDL Number]
MFCD29047135 | [MOL File]
1050477-31-0.mol | [Molecular Weight]
378.42 |
| Chemical Properties | Back Directory | [Boiling point ]
554.7±50.0 °C(Predicted) | [density ]
1.29±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
DMF: 10 mg/ml DMSO: 3 mg/ml Ethanol: insol PBS (pH 7.2): insol | [form ]
solid | [pka]
14.76±0.40(Predicted) | [color ]
White to off-white | [λmax]
255 nm | [InChI]
InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1 | [InChIKey]
BTBHLEZXCOBLCY-QGZVFWFLSA-N | [SMILES]
N1C2=C(C(OCC)=NC=C2C)[C@H](C2=CC=C(C#N)C=C2OC)C(C(N)=O)=C1C |
| Hazard Information | Back Directory | [Description]
Finerenone(1050477-31-0) is a novel mineralocorticoid receptor antagonist that has the effect of delaying the progression of chronic kidney disease. Some people may be aware of two other mineralocorticoid receptor antagonists: the diuretic antihypertensive drug spironolactone, and eplerenone.Finerenone is their cognate derivative and is a third-generation mineralocorticoid receptor antagonist. So far, finerenone is the only nonsteroidal mineralocorticoid receptor antagonist to be FDA approved. ?Finerenone was granted FDA approval on 9 July 2021, followed by the EMA approval on 11 March 2022. | [Uses]
Finerenone is the first non-steroidal selective mineralocorticoid receptor antagonist, which can be used for the treatment of diabetic nephropathy, chronic kidney disease and end-stage renal disease. It can reduce the proteinuria of patients and improve the glomerular filtration rate. | [Brand name]
Finerenone is sold under the brand name Kerendia and Firialta. | [Biological Activity]
Finerenone (FIN, BAY 94-8862) is a highly selective, orally active, nonsteroidal antagonist of mineralocorticoid receptor (MR) with IC50 of 18 nM. Finerenone has the potential to study cardio-renal diseases such as type 2 diabetes and chronic kidney disease. | [in vivo]
Finerenone (BAY 94-8862) lowers albuminuria by >40% and significantly reduces systolic blood pressure (SBP) in Munich Wistar Fr?mter (MWF) rat. | [Mode of action]
Finerenone is a Nonsteroidal Mineralocorticoid-Receptor Antagonist. The mechanism of action of finerenone is as a Mineralocorticoid Receptor Antagonist. Finerenone inhibits the effects of mineralocorticoids like aldosterone and cortisol when the MR is overactivated, possibly reducing inflammation and fibrosis in the heart and kidney. | [References]
Kolkhof, P., Hartmann, E., Freyberger, A., et al.Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am. J. Nephrol. 52(8), 642-652 (2021).
DOI: 10.1159/000516213
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. |
|
|